CoChat

Diabetes and Pregnancy: An Endocrine Society Clinical Practice Guideline

Open access
Blumer, Ian, Hadar, Eran, Hadden, David R, Jovanovič, Lois, Mestman, Jorge H, Murad, M Hassan, Yogev, Yariv · 2013 · The Journal of Clinical Endocrinology & Metabolism

The DOI matches its Crossref record; 238 of the 265 references it cites were found in a registry or an index; 17 of the 323 sources its claims cite were checked for support.

Abstract

Objective: Our objective was to formulate a clinical practice guideline for the management of the pregnant woman with diabetes. Participants: The Task Force was composed of a chair, selected by the Clinical Guidelines Subcommittee of The Endocrine Society, 5 additional experts, a methodologist, and a medical writer. Evidence: This evidence-based guideline was developed using the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) system to describe both the strength of recommendations and the quality of evidence. Consensus Process: One group meeting, several conference calls, and innumerable e-mail communications enabled consensus for all recommendations save one with a majority decision being employed for this single exception. Conclusions: Using an evidence-based approach, this Diabetes and Pregnancy Clinical Practice Guideline addresses important clinical issues in the contemporary management of women with type 1 or type 2 diabetes preconceptionally, during pregnancy, and in the postpartum setting and in the diagnosis and management of women with gestational diabetes during and after pregnancy.

Overview

CoChat Summary

TL;DR

This Endocrine Society clinical practice guideline provides evidence-based recommendations for managing type 1 or type 2 diabetes preconceptionally, during pregnancy, and postpartum, and for diagnosing and managing gestational diabetes. It uses GRADE and recommends universal early diabetes testing, 24–28 week 75-g OGTT with IADPSG criteria, tight glycemic targets, and lifestyle-first therapy with insulin or selected oral agents when needed.

Key findings

  • Universal testing for overt diabetes is recommended at the first prenatal visit before 13 weeks (or as soon as possible thereafter) using fasting plasma glucose, HbA1c, or untimed random plasma glucose; overt diabetes thresholds are fasting ≥126 mg/dL (≥7.0 mmol/L), random ≥200 mg/dL (≥11.1 mmol/L), or HbA1c ≥6.5%, while early gestational diabetes is fasting 92–125 mg/dL (5.1–6.9 mmol/L).
  • Gestational diabetes should be tested at 24–28 weeks with a 2-hour 75-g OGTT and diagnosed using IADPSG criteria: fasting 92–125 mg/dL (5.1–6.9 mmol/L), 1-hour ≥180 mg/dL (≥10.0 mmol/L), or 2-hour 153–199 mg/dL (8.5–11.0 mmol/L).
  • Glycemic targets are preprandial ≤95 mg/dL (5.3 mmol/L), or ≤90 mg/dL (5.0 mmol/L) if safely achievable; 1-hour postmeal ≤140 mg/dL (7.8 mmol/L); 2-hour postmeal ≤120 mg/dL (6.7 mmol/L); and for overt diabetes HbA1c ≤7% (ideally ≤6.5%).
  • Initial gestational diabetes treatment is medical nutrition therapy plus ≥30 minutes daily moderate exercise; pharmacotherapy is recommended if lifestyle is insufficient, with insulin preferred for diagnosis before 25 weeks or fasting plasma glucose >110 mg/dL (6.1 mmol/L), glyburide as a suitable alternative in other cases, and metformin restricted to women who refuse or cannot use insulin or glyburide and are not in the first trimester.

Methods

  • The Endocrine Society appointed a Task Force composed of a chair, 5 additional experts, a methodologist, and a medical writer; it used the GRADE system to grade strength of recommendations and quality of evidence.
  • The Task Force commissioned two systematic reviews and developed recommendations through one group meeting, several conference calls, and email communications; consensus was achieved for all recommendations except one, which used a majority decision.
  • The commissioned reviews included a screening review of 39 original studies enrolling 87,830 women and a glucose-targets review of 34 original studies enrolling 9,433 women (15 randomized controlled trials, 18 cohort studies, and 1 case-control study).

Limitations

  • Stated in the text: the quality of evidence for screening remains low because no randomized trials compared screening vs no screening and measured patient-important outcomes; the glucose-targets analysis could not control for maternal BMI and had significant heterogeneity, with sparse data for type 1 and type 2 diabetes and postprandial targets.
  • Stated in the text: the recommendation to adopt IADPSG criteria was a majority opinion, not unanimous, and is acknowledged as arguable and controversial; implementation will substantially increase gestational diabetes diagnoses, medicalization of pregnancies, and healthcare costs.
  • Evident from the text: many recommendations are ungraded or based on indirect evidence, unsystematic observations, or consensus; some key management recommendations rely on observational studies, and long-term safety data for metformin use in pregnancy are not yet available.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1210/jc.2013-2465

Cites

238 of 238 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Verification

Claims the paper makes

10 Valid · 1 Not valid · 138 Not checked · 19 Own results and interpretations

129 more claims · 4 with their cited sources checked

Create a free account to see all 168 claims and to verify the 302 references still open.

See all claims — free account
  • It may state two separate claims as one. 28
  • Probably not a substantial claim. 8

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

1 retracted

Show all 238 references

Research works printed but not linked: 8

  1. Langer, 2000, Level of glycemia and perinatal outcome in pregestational diabetes, J Matern Fetal Med, 9, 35, 10.1002/(SICI)1520-6661(200001/02)9:1<35::AID-MFM8>3.0.CO;2-6 · doi:10.1002/(sici)1520-6661(200001/02)9:1
  2. Confidential Enquiry into Maternal and Child Health (CEMACH), 2007, Diabetes in Pregnancy: Are We Providing the Best Care? Findings of a National Enquiry: England, Wales and Northern Ireland
  3. Leguizamon, 2000, Effect of medical therapy on progressive nephropathy: influence of pregnancy, diabetes and hypertension, J Matern Fetal Med, 9, 70, 10.1002/(SICI)1520-6661(200001/02)9:1<70::AID-MFM15>3.0.CO;2-# · doi:10.1002/(sici)1520-6661(200001/02)9:1
  4. Voelmle, 2007, Fetal outcomes and improved A1c values in pregnant women with type 1 diabetes using real-time continuous glucose sensors, Diabetes, 56, A117
  5. American Dietetic Association, 2002, Nutrition Practice Guidelines for Gestational Diabetes [CD-ROM]
  6. American Diabetes Association, 2000, American Diabetes Association: gestational diabetes (position statement), Diabetes Care, 23, S77
  7. Mimouni, 1987, Perinatal asphyxia in infants of diabetic mothers is associated with maternal vasculopathy and hyperglycaemia in labour, Neonat Epidemiol Follow-up, 400A
  8. Mayer-Davis, 2006, Breast-feeding and risk for childhood obesity: does maternal diabetes or obesity status matter?, Diabetes Care, 29, 2231, 10.2337/dc06-0974 · DOI · Paper page

Cited by

Metadata

Authors
Blumer, I., Hadar, E., Hadden, D. R., Jovanovič, L., Mestman, J. H., Murad, M. H., & Yogev, Y.
Affiliations
  • Charles H. Best Diabetes Centre (I.B.), Whitby, Ontario, Canada L1M 1Z5
  • Helen Schneider Hospital for Women (E.H., Y.Y.), Petach Tikva 49100, Israel
  • Royal Victoria Hospital (GB)
  • Sansum Diabetes Research Institute (US)
  • University of Southern California (US)
  • Mayo Clinic (US)
Venue
The Journal of Clinical Endocrinology & Metabolism
Published
2013-11-01
Volume
98
Issue
11
Pages
4227-4249
ISSN
  • 0021-972X (ISSN-L)
  • 1945-7197
OpenAlex
W2109023860
Cited by
561
References
265
Citations by year
2026: 9 · 2025: 30 · 2024: 40 · 2023: 42 · 2022: 61 · 2021: 46 · 2020: 47 · 2019: 62 · 2018: 55 · 2017: 43 · 2016: 46 · 2015: 47 · 2014: 28 · 2013: 2
FWCI
45.55
Type
journal article
Language
en
Open access
Locations
  • The Journal of Clinical Endocrinology & Metabolism (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Obstetrics and Gynecology › Gestational Diabetes Research and Management
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Pregnancy and Medication Impact
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
Keywords
diabetes in pregnancy, gestational diabetes mellitus, type 1 diabetes, type 2 diabetes, preconception care, postpartum care, glycemic control, diabetes management in pregnancy
MeSH terms
Endocrinology, Female, Humans, Pregnancy, Pregnancy in Diabetics, Societies, Medical, Practice Guidelines as Topic, Evidence-Based Medicine

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-04, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-04 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.